Nov 22, 2021
2:39:41am
2:39:41am
Lol, haven’t been on Facebook since I was fresh outta high school and single.
No they’re not the same. One will cost a small fortune and the other you can get for pennies on the dollar. The protein inhibitors work in essentially the same way and are both effective. Links included to all the studies. Would love a medical professional to chime in on how these points are wrong. Always willing to learn
First of all, according to the US government, ivermectin works well against COVID-19 . If something can aid in ending the pandemic, why has it been slandered so much? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248252/
“Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Meta-analysis of 15 trials, assessing 2438 participants, found that ivermectin reduced the risk of death by an average of 62%
Meta-analysis of these 3 trials, assessing 738 participants, found that ivermectin prophylaxis among health care workers and COVID-19 contacts probably reduces the risk of COVID-19 infection by an average of 86%”
Comparing the 2 drugs. New Pfizer antiviral and ivermectin, a pharmacodynamic analysis:
New Pfizer antiviral, PF-07321332, C₂₃H₃₂F₃N₅O₄
PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease,
So, what is a protease?
So what is a protease inhibitor?
And, what is 3CL?
Chymotrypsin-like protease (3CL main protease, or 3CL Mpro)
Identification of SARS-CoV‑2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening (3rd September 2020)
The activity of the anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds
Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection
the strength and persistency of the interaction between IVE and the binding site of 3CLpro indicate that a partial inhibition of the catalytic activity could have place as the drug interacts with the main subdomains that define the enzyme binding pocket:
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
as shown in Fig. 4, out of 13 OTDs only ivermectin completely blocked ( more than 80%) the 3CLpro activity at 50 µM concentration.
Development, validation, and approval of COVID-19 specific drugs takes years. Therefore, the idea of drug repositioning, also known as repurposing, is an important strategy to control the sudden outbreak of life-threatening infectious agents that spread rapidly.
Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: designing, docking and molecular dynamics simulation study
From the docking analysis, ivermectin showed the highest docking score with an average energy of −8.5 kcal mol−1 among all the compounds. Remdesivir showed the lowest binding energy and highest docking score of −9.9 kcal mol−1
Ritonavir, C37H48N6O5S2
Ivermectin, C48H74O14
Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach
Documented here is an intense binding of both ivermectin B1a and B1b isomer to the main protease with subsequent energy (ETot-) values of -384.56 and -408.6.
PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease,
Risk of virus developing resistance to PF-07321332
Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2
With SARS-CoV-2 S Spike protein
Ivermectin showed high binding affinity to the viral S protein as well as the human cell surface receptors ACE-2 and TMPRSS2.
In agreement to these findings, ivermectin was found to be docked between the viral spike and the ACE2 receptor
Binding Interactions of Selected Drugs With Human TMPRSS2 Protein (ACE2 protein)
The docking results revealed that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −174.971) and protein–ligand interactions
Binding Interactions of Selected Drugs With Human ACE-2 Protein
that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −159.754) and protein–ligand interactions
With SARS-CoV-2 S Glycoprotein
Ivermectin showed the highest binding affinity to the predicted active site of the protein
With SARS-CoV-2 Nsp14 Protein
ivermectin showed the highest binding affinity (MolDock score −212.265) and protein–ligand interactions
Binding Interactions of Selected Drugs With SARS-CoV-2 PLpro
Ivermectin showed the highest binding affinity to the predicted active site of the protein (MolDock score −180.765) and protein–ligand interactions
First of all, according to the US government, ivermectin works well against COVID-19 . If something can aid in ending the pandemic, why has it been slandered so much? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248252/
“Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Meta-analysis of 15 trials, assessing 2438 participants, found that ivermectin reduced the risk of death by an average of 62%
Meta-analysis of these 3 trials, assessing 738 participants, found that ivermectin prophylaxis among health care workers and COVID-19 contacts probably reduces the risk of COVID-19 infection by an average of 86%”
Comparing the 2 drugs. New Pfizer antiviral and ivermectin, a pharmacodynamic analysis:
New Pfizer antiviral, PF-07321332, C₂₃H₃₂F₃N₅O₄
PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease,
So, what is a protease?
So what is a protease inhibitor?
And, what is 3CL?
Chymotrypsin-like protease (3CL main protease, or 3CL Mpro)
Identification of SARS-CoV‑2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening (3rd September 2020)
The activity of the anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds
Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection
the strength and persistency of the interaction between IVE and the binding site of 3CLpro indicate that a partial inhibition of the catalytic activity could have place as the drug interacts with the main subdomains that define the enzyme binding pocket:
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
as shown in Fig. 4, out of 13 OTDs only ivermectin completely blocked ( more than 80%) the 3CLpro activity at 50 µM concentration.
Development, validation, and approval of COVID-19 specific drugs takes years. Therefore, the idea of drug repositioning, also known as repurposing, is an important strategy to control the sudden outbreak of life-threatening infectious agents that spread rapidly.
Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: designing, docking and molecular dynamics simulation study
From the docking analysis, ivermectin showed the highest docking score with an average energy of −8.5 kcal mol−1 among all the compounds. Remdesivir showed the lowest binding energy and highest docking score of −9.9 kcal mol−1
Ritonavir, C37H48N6O5S2
Ivermectin, C48H74O14
Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach
Documented here is an intense binding of both ivermectin B1a and B1b isomer to the main protease with subsequent energy (ETot-) values of -384.56 and -408.6.
PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease,
Risk of virus developing resistance to PF-07321332
Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2
With SARS-CoV-2 S Spike protein
Ivermectin showed high binding affinity to the viral S protein as well as the human cell surface receptors ACE-2 and TMPRSS2.
In agreement to these findings, ivermectin was found to be docked between the viral spike and the ACE2 receptor
Binding Interactions of Selected Drugs With Human TMPRSS2 Protein (ACE2 protein)
The docking results revealed that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −174.971) and protein–ligand interactions
Binding Interactions of Selected Drugs With Human ACE-2 Protein
that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −159.754) and protein–ligand interactions
With SARS-CoV-2 S Glycoprotein
Ivermectin showed the highest binding affinity to the predicted active site of the protein
With SARS-CoV-2 Nsp14 Protein
ivermectin showed the highest binding affinity (MolDock score −212.265) and protein–ligand interactions
Binding Interactions of Selected Drugs With SARS-CoV-2 PLpro
Ivermectin showed the highest binding affinity to the predicted active site of the protein (MolDock score −180.765) and protein–ligand interactions
Originally posted on Nov 22, 2021 at 2:39:41am
Message modified by bigbossbyu on Nov 22, 2021 at 2:40:04am
Message modified by bigbossbyu on Nov 22, 2021 at 2:48:05am
Message modified by bigbossbyu on Nov 22, 2021 at 2:57:05am
Message modified by bigbossbyu on Nov 22, 2021 at 2:58:22am
Message modified by bigbossbyu on Nov 22, 2021 at 2:59:21am
- Bio page
- bigbossbyu
- Joined
- Jan 11, 2016
- Last login
- May 6, 2024
- Total posts
- 7,914 (14 FO)
Messages
Time
11/21/21 9:53pm
11/21/21 11:40pm
11/21/21 9:42pm
11/21/21 9:43pm
11/21/21 9:43pm
11/21/21 10:04pm
11/21/21 11:30pm
11/21/21 9:59pm
11/21/21 11:37pm
11/22/21 6:17am